Nuveen Asset Management, LLC Halozyme Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 1,530,519 shares of HALO stock, worth $92.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,530,519

Previous 1,539,153 0.56%

Holding current value

$92.1 Million

Previous $88.1 Million 16.9%

% of portfolio

0.02%

Previous 0.03%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$42.57 - $61.09 $367,549 - $527,451	-8,634 Reduced 0.56%	1,530,519 $73.2 Million
Q3 2024 Nov 14, 2024	SELL	$51.3 - $64.42 $3.2 Million - $4.02 Million	-62,445 Reduced 3.9%	1,539,153 $88.1 Million
Q2 2024 Aug 09, 2024	SELL	$37.81 - $52.4 $1.89 Million - $2.62 Million	-50,012 Reduced 3.03%	1,601,598 $83.9 Million
Q1 2024 May 13, 2024	BUY	$33.68 - $41.95 $4.26 Million - $5.3 Million	126,408 Added 8.29%	1,651,610 $67.2 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $654,538 - $827,012	-19,644 Reduced 1.27%	1,525,202 $56.4 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $6.64 Million - $8.02 Million	182,141 Added 13.37%	1,544,846 $59 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $3.88 Million - $4.96 Million	128,147 Added 10.38%	1,362,705 $49.2 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $7.85 Million - $13.3 Million	239,022 Added 24.01%	1,234,558 $47.1 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $1.6 Million - $2.38 Million	-39,987 Reduced 3.86%	995,536 $56.6 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $798,611 - $1.07 Million	20,727 Added 2.04%	1,035,523 $40.9 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $2 Million - $2.58 Million	53,462 Added 5.56%	1,014,796 $44.7 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $287,218 - $368,883	-8,984 Reduced 0.93%	961,334 $35.8 Million
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $1.32 Million - $1.69 Million	-41,490 Reduced 4.1%	970,318 $39 Million
Q3 2021 Nov 12, 2021	BUY	$38.47 - $46.42 $3.6 Million - $4.34 Million	93,456 Added 10.18%	1,011,808 $41.2 Million
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $1.04 Million - $1.38 Million	26,846 Added 3.01%	918,352 $41.7 Million
Q1 2021 May 17, 2021	SELL	$39.51 - $51.45 $4.91 Million - $6.39 Million	-124,205 Reduced 12.23%	891,506 $37.2 Million
Q4 2020 May 17, 2021	BUY	$25.81 - $43.62 $1.36 Million - $2.3 Million	52,637 Added 5.47%	1,015,711 $43.4 Million
Q4 2020 Feb 16, 2021	SELL	$25.81 - $43.62 $1.98 Million - $3.34 Million	-76,546 Reduced 7.36%	963,074 $41.1 Million
Q3 2020 Nov 16, 2020	BUY	$25.74 - $29.63 $309,986 - $356,834	12,043 Added 1.17%	1,039,620 $27.3 Million
Q2 2020 Aug 14, 2020	SELL	$16.25 - $26.81 $1.06 Million - $1.75 Million	-65,325 Reduced 5.98%	1,027,577 $27.5 Million
Q1 2020 May 14, 2020	SELL	$13.9 - $21.83 $4.65 Million - $7.3 Million	-334,423 Reduced 23.43%	1,092,902 $19.7 Million
Q4 2019 Feb 14, 2020	BUY	$14.93 - $19.53 $2.42 Million - $3.16 Million	161,984 Added 12.8%	1,427,325 $25.3 Million
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $3.36 Million - $3.9 Million	-220,740 Reduced 14.85%	1,265,341 $19.6 Million
Q2 2019 Aug 15, 2019	BUY	$14.75 - $17.26 $21.9 Million - $25.6 Million	1,486,081 New	1,486,081 $25.5 Million
Q3 2018 Nov 13, 2018	SELL	$16.68 - $18.41 $381,688 - $421,276	-22,883 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $16,245 - $19,548	-963 Reduced 4.04%	22,883 $386,000
Q4 2017 Feb 14, 2018	BUY	$16.75 - $20.8 $399,420 - $495,996	23,846	23,846 $0

Others Institutions Holding HALO

# of Institutions

550

Shares Held

124M

Call Options Held

668K

Put Options Held

259K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.38B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Halozyme Therapeutics, Inc. Transaction History